000 06474cam a2200805Ka 4500
001 ocn714798782
003 OCoLC
005 20171119092411.0
006 m o d
007 cr cn|||||||||
008 110426s2011 gw ob 001 0 eng d
020 _a9783527633166
_q(electronic bk.)
020 _a3527633162
_q(electronic bk.)
020 _a9783527633173
020 _a3527633170
020 _a1283140578
020 _a9781283140577
020 _a9783527326037
_q(hbk.)
020 _a3527326030
_q(hbk.)
024 8 _a9786613140579
029 1 _aAU@
_b000047551145
029 1 _aNZ1
_b15916510
029 1 _aDEBBG
_bBV043393011
035 _a(OCoLC)714798782
_z(OCoLC)700706105
_z(OCoLC)702389973
_z(OCoLC)740225688
_z(OCoLC)741453982
_z(OCoLC)816845189
037 _a10.1002/9783527633166
_bWiley InterScience
_nhttp://www3.interscience.wiley.com
040 _aDG1
_beng
_epn
_cDG1
_dMERUC
_dEBLCP
_dTXA
_dOCLCQ
_dOCLCF
_dOCLCA
_dOCLCQ
_dIDEBK
_dU3G
_dYDXCP
_dN$T
_dE7B
_dMHW
_dCDX
_dOCLCQ
_dCOO
_dOCLCQ
_dDEBBG
049 _aMAIN
050 4 _aRM301.57
_b.P76 2011eb
060 4 _aQV 785
_bP962 2011
072 7 _aMED
_x023000
_2bisacsh
072 7 _aMED
_x071000
_2bisacsh
072 7 _aMED
_x072000
_2bisacsh
072 7 _aMED
_x058170
_2bisacsh
082 0 4 _a615.191
_222
245 0 0 _aProdrugs and Targeted Delivery : Towards Better ADME Properties /
_h[electronic resource]
260 _aWeinheim :
_bWiley-VCH,
_c©2011.
300 _a1 online resource (522 pages).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aMethods and Principles in Medicinal Chemistry ;
_v[47]
504 _aIncludes bibliographical references (pages 473-481) and index.
505 0 _aFront Matter -- Prodrug Design and Intellectual Property. Prodrug Strategies in Drug Design / Jarkko Rautio -- The Molecular Design of Prodrugs by Functional Group / Victor R Guarino -- Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites / Eyal H Barash -- Prodrugs Addressing ADMET Issues. Increasing Lipophilicity for Oral Drug Delivery / Majid Y Moridani -- Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery / Victor R Guarino -- Prodrugs Designed to Target Transporters for Oral Drug Delivery / Mark S Warren, Jarkko Rautio -- Topical and Transdermal Delivery Using Prodrugs: Mechanism of Enhancement / Kenneth Sloan, Scott C Wasdo, Susruta Majumdar -- Ocular Delivery Using Prodrugs / Deep Kwatra, Ravi Vaishya, Ripal Gaudana, Jwala Jwala, Ashim K Mitra -- Reducing Presystemic Drug Metabolism / Majid Y Moridani -- Enzyme-Activated Prodrug Strategies for Site-Selective Drug Delivery / Krista Laine, Kristiina Huttunen -- Prodrug Approaches for Central Nervous System Delivery / Quentin R Smith, Paul R Lockman -- Directed Enzyme Prodrug Therapies / Dan Niculescu-Duvaz, Gabriel Negoita-Giras, Ion Niculescu-Duvaz, Douglas Hedley, Caroline J Springer -- Codrugs and Soft Drugs. Improving the Use of Drug Combinations Through the Codrug Approach / Peter A Crooks, Harpreet K Dhooper, Ujjwal Chakraborty -- Soft Drugs / Paul W Erhardt, Michael D Reese -- Preclinical and Clinical Consideration for Prodrugs. Pharmacokinetic and Biopharmaceutical Considerations in Prodrug Discovery and Development / John P O'Donnell -- The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs / Jane P F Bai, Mike Pacanowski, Atiqur Rahman, Lawrence L Lesko -- Index.
505 0 _aProdrugs and Targeted Delivery: Towards Better ADME Properties; Contents; List of Contributors; Preface; A Personal Foreword; Part One: Prodrug Design and Intellectual Property; 1 Prodrug Strategies in Drug Design; 2 The Molecular Design of Prodrugs by Functional Group; 3 Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites; Part Two: Prodrugs Addressing ADMET Issues; 4 Increasing Lipophilicity for Oral Drug Delivery; 5 Modulating Solubility Through Prodrugs for Oral and IV Drug Delivery.
505 8 _a6 Prodrugs Designed to Target Transporters for Oral Drug Delivery7 Topical and Transdermal Delivery Using Prodrugs: Mechanism of Enhancement; 8 Ocular Delivery Using Prodrugs; 9 Reducing Presystemic Drug Metabolism; 10 Enzyme-Activated Prodrug Strategies for Site-Selective Drug Delivery; 11 Prodrug Approaches for Central Nervous System Delivery; 12 Directed Enzyme Prodrug Therapies; Part Three: Codrugs and Soft Drugs; 13 Improving the Use of Drug Combinations Through the Codrug Approach; 14 Soft Drugs; Part Four: Preclinical and Clinical Consideration for Prodrugs.
505 8 _a15 Pharmacokinetic and Biopharmaceutical Considerations in Prodrug Discovery and Development16 The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs; Index.
520 _aThis topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies for the rational design of prodrugs, beginning at the early stages of the development process, as well as discussing organ- and site-selective prodrugs. Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development.
588 0 _aPrint version record.
650 0 _aProdrugs.
650 0 _aPharmacy.
650 0 _aMedicine.
650 2 2 _aProdrugs.
650 2 2 _aDrug Delivery Systems.
650 7 _aMEDICAL
_xDrug Guides.
_2bisacsh
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aMEDICAL
_xPharmacy.
_2bisacsh
650 7 _aMEDICAL
_xNursing
_xPharmacology.
_2bisacsh
650 7 _aMedicine.
_2fast
_0(OCoLC)fst01014893
650 7 _aPharmacy.
_2fast
_0(OCoLC)fst01060285
650 7 _aProdrugs.
_2fast
_0(OCoLC)fst01078135
655 4 _aElectronic books.
700 1 _aRautio, Jarkko.
700 1 _aMannhold, Raimund,
_d1948-
700 1 _aKubinyi, Hugo.
710 2 _aWiley InterScience (Online service)
776 0 8 _iPrint version:
_aRautio, Jarkko.
_tProdrugs and Targeted Delivery.
_dWeinheim : Wiley-VCH, 2010
_z9783527633173
_w(OCoLC)700706105
830 0 _aMethods and principles in medicinal chemistry.
856 4 0 _uhttp://onlinelibrary.wiley.com/book/10.1002/9783527633166
_zWiley Online Library
942 _2ddc
_cBK
999 _c204999
_d204999